The American Journal of Managed Care10 天
A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins
Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver ...
BioWorld1 个月
Switch Therapeutics nominates liver-sparing APOE RNAi therapy as development candidate for ...
Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...